"Pharmacokinetic Study of Nicotinamide Riboside"

Status Completed

Clinical Trial Summary

Nicotinamide riboside (NR) has been available over the counter as a nutraceutical (Niagen®, ChromaDex, Inc.) since the summer of 2013. However, classical pharmacokinetic (PK) data for NR have not been reported in humans. This study will use a recently-developed, whole blood assay for NR to assess the pharmacokinetics of NR at a maximum dose of 1000 mg twice daily, and will collect history, physical examination and laboratory data to determine the safety and tolerability of NR in eight, healthy volunteers. In addition, whole blood nicotinamide adenine dinucleotide (NAD) levels will be measured at each time point, to determine whether this NR dose significantly raises whole blood NAD levels.

Clinical Trial Description

1. On Day 1, participants will have a baseline assessment, including blood pressure and heart rate, as well as baseline assessment of "safety" labs: complete blood count with white blood count differential and platelets, serum chemistry panel (sodium, potassium, chloride, glucose, blood urea nitrogen and creatinine), uric acid, creatine kinase, aspartate aminotransferase and alanine aminotransferase, and lactate dehydrogenase.

2. Participants will receive 250 mg nicotinamide riboside (NR) by mouth daily on Days 1-2, 250 mg NR by mouth twice daily on Days 3-4, 500 mg NR twice daily by mouth on Days 5-6 and 1000 mg NR twice daily by mouth on Days 7-8.

3. On Day 2, a blood sample will be obtained from each participant to measure serum chemistry panel to assess for the possibility of hyperkalemia and hyperglycemia. In addition, an instant read potassium will be measured using a point-of-care device available on the University of Washington (UW) General Clinical Research Center (GCRC). If the potassium is greater than 5.5, a repeat value and an ECG will be performed and the Study Investigator. If it is greater than 6.0, the Study Investigator will evaluate the subject for admission.

4. On Day 9 prior to receiving their morning dose, participants will be admitted to the UW GCRC for an overnight stay.

1. In the UW GCRC, the participants will receive the last 1000 mg dose of NR at time=0.

2. Blood samples will be collected at time = 30 minutes and at 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours.

3. Whole blood samples will be frozen at -80 degrees C until assayed for NR and NAD+.

4. "Safety labs" performed on Day 1 will be repeated ;

Study Design

Related Conditions & MeSH terms

Metabolic Disturbance

Clinical Trial Details

NCT number	NCT02689882
Study type	Interventional
Source	University of Washington
Contact
Status	Completed
Phase	Phase 1
Start date	November 2015
Completion date	February 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04528004` - Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure	Early Phase 1
Completed	`NCT04597983` - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists	N/A
Completed	`NCT03445234` - Blueberries, Bananas, Exercise Recovery	N/A
Recruiting	`NCT04892199` - Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?	Phase 4
Active, not recruiting	`NCT05070585` - Isothiocyanates and Metabolic Health	Phase 1/Phase 2
Not yet recruiting	`NCT05494151` - Metabolic Substrate of Patients With Myocardial Infarction With and Without Modifiable Cardiovascular Risk Factors
Completed	`NCT04787952` - Insight Into New Brown Adipose Tissue Activators.
Completed	`NCT05758857` - Multiple Risk Factor Intervention Trial	N/A
Completed	`NCT01674426` - Pathogenesis of Functional Hypothalamic Amenorrhea	N/A
Recruiting	`NCT06252922` - Diet-Induced Changes in GEnetic Material
Completed	`NCT06326840` - Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment	N/A
Recruiting	`NCT06345937` - Multiple Risk Factor Intervention Trial (Ms. FIT)	N/A
Recruiting	`NCT06392360` - Betaine, Exercise Performance, and Gut Permeability	N/A
Completed	`NCT04009642` - Cardiac Rest and Stress Metabolism in Patients With Type 2 Diabetes
Withdrawn	`NCT03515642` - Exercise, Gut Microbiota in Sedentary Adults With Overweight	N/A
Recruiting	`NCT06333184` - Smoothies and Blood Sugars	N/A
Not yet recruiting	`NCT05773183` - Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
Completed	`NCT04266665` - Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome	Phase 4
Completed	`NCT03697928` - Markers of Carnitine Acetyltransferase (CrAT) Protein Activity and Carnitine Availability
Recruiting	`NCT04469790` - Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.